Citation only
via Europe PMC
Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes.
Lee CM, Kim JY, Shim JH, Cho GW.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2026
Abstract
<h4>Abstract</h4>The global rise in aging populations has been accompanied by increasing rates of obesity and type 2 diabetes, both of which pose significant public health and economic challenges. This review aims to investigate the pathophysiological link between obesity and diabetes and evaluate emerging therapeutic strategies that involve glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, including their dual and triple agonist developments. A comprehensive literature review was conducted focusing on the mechanisms of glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, their clinical efficacy, and the evolution of combination therapies. Emphasis was placed on recent clinical trials and the development of oral agonist formulations to improve patient compliance. Glucagon-like peptide-1 receptor agonists, such as semaglutide and liraglutide, promote insulin secretion, suppress appetite, and result in effective weight loss and glycemic control. Semaglutide is available in both injectable and oral forms, improving accessibility. Liraglutide also reduces cardiovascular risk. Melanocortin-4 receptor agonists act via the central nervous system to reduce appetite and increase energy expenditure, with setmelanotide showing efficacy in genetic obesity. Dual and triple agonists, such as tirzepatide, simultaneously target glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors, leading to enhanced metabolic outcomes. Oral drugs like rybelsus improve long-term adherence. Glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, particularly when used as dual or triple agents, represent promising therapeutic innovations for obesity and type 2 diabetes. The development of oral formulations further enhances treatment convenience and adherence, paving the way for improved clinical outcomes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1055/a-2928-5204
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
CM, L., JY, K., JH, S., & GW., C. (2026). Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes. <em>Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme</em>. https://doi.org/10.1055/a-2928-5204
Vancouver
CM L, JY K, JH S, GW. C. Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2026. doi:10.1055/a-2928-5204.
BibTeX
@article{lee2026Recent,
title = {Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes.},
author = {Lee CM and Kim JY and Shim JH and Cho GW.},
journal = {Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme},
year = {2026},
doi = {10.1055/a-2928-5204},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
JAMA 2025
Preprint · OA
Diagnosis and Treatment of Type 2 Diabetes in Adults
World Journal of Cardiology 2015
Open access · CC-BY
Therapeutic modification of arterial stiffness: An update and comprehensive review
Journal of Obesity & Metabolic Syndrome 2023
Open access · CC-BY
Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Circulation 2011
Open access · OA
Rhesus Macaques Develop Metabolic Syndrome With Reversible Vascular Dysfunction Responsive to Pioglitazone
Journal of Endocrinological Investigation 2025
Open access · CC-BY
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
International Journal For Multidisciplinary Research 2025
Open access · CC-BY